TTI-0102

VA Office of Research and Development · Phase 2 active Small molecule

At a glance

Generic name	TTI-0102
Also known as	cysteamine-pantetheine disulfide
Sponsor	VA Office of Research and Development
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Assess TTI-0102 vs Placebo in MELAS Patients (PHASE2)
A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS) (PHASE2)
Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19 (PHASE2)
TTI-0102 for Veterans With TBI (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TTI-0102 CI brief — competitive landscape report
TTI-0102 updates RSS · CI watch RSS
VA Office of Research and Development portfolio CI